Related Experiment Video
Updated: May 11, 2026
16:41
Experimental Approaches to Tissue Engineering
Published on: August 30, 2007
Continuing to strengthen FDA's science approach to emerging technologies
Rachael Anatol1, Steven Bauer, Suzanne Epstein
1Emerging Technology Programs, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD, USA.
Nanomedicine : Nanotechnology, Biology, and Medicine
|May 23, 2013
Summary
Emerging technologies drive medical product innovation. The U.S. Food and Drug Administration (FDA) supports this by investing in research and collaboration to ensure safe and effective public health advancements.
Area of Science:
- Biomedical Engineering
- Regulatory Science
- Medical Innovation
Background:
- Technological advances and innovation lead to emerging technologies.
- These technologies stimulate novel research in medical product development.
- New manufacturing approaches and improved product quality often result.
Purpose of the Study:
- To highlight the role of emerging technologies in medical product development.
- To outline the U.S. Food and Drug Administration's (FDA) critical function in this process.
- To emphasize the importance of FDA's investments in fostering innovation.
Main Methods:
- The abstract discusses the impact of emerging technologies on medical products.
- It highlights the FDA's strategic investments and support mechanisms.
- Focus is on regulatory science, agency coordination, and stakeholder engagement.
Main Results:
- Emerging technologies are key drivers for novel medical product development.
- FDA's support, including investments in coordination, training, and research, is crucial.
- These efforts translate innovations into safe and effective medical products.
Conclusions:
- The FDA plays a vital role in leveraging emerging technologies for public health.
- Strategic investments by the FDA accelerate the translation of innovation into medical products.
- Collaboration and regulatory science are essential for ensuring product safety and efficacy.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...